Kamal

Mariposa Therapeutics

This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.

BioMendics

BioMendics develops liquid crystal small molecule therapeutics for patients suffering from rare genetic dermatologic disorders such as epidermolysis bullosa simplex.

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Orvida Pharma (Formerly Kamari)

This biotechnology company develops oral and topical small-molecule treatments for patients with rare and severe genetic skin diseases and chronic itch conditions.

Castle Creek Biosciences

This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.

Aegle Therapeutics

This company develops extracellular vesicle therapies derived from stem cells to treat patients with rare dermatological disorders and severe burns.

Kamau Therapeutics

This company develops clinical-stage gene correction therapies using targeted DNA integration to treat patients with sickle cell disease and other genetic conditions.

HemaB

Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.